Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer
(NSCLC). However, no associated biomarker is validated in clinical practice with this drug…

Hedgehog signaling pathway is physiologically activated during embryogenesis, especially
in lung development. It is also reactivated in many solid tumors. In lung cancer, Hedgehog …

Introduction Sequential anti–programmed cell death protein 1 (PD-1) or anti–programmed
death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased …

Original research: Sequential ctDNA whole-exome sequencing in advanced lung
adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late …

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients
with non-small cell lung cancer (NSCLC). Although some patients can experience important …

Simple Summary Wnt and Hedgehog (Hh) pathways are associated with stemness profile
and with resistance to anti-tumor therapies. Pre-clinical data have suggested a role of these …

Lung cancer is very common and the most common cause of cancer death worldwide.
Despite recent progress in the systemic treatment of lung cancer (checkpoint inhibitors and …

Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in
phase III trials showed 50% progression at first evaluation, but better overall survival (OS), …

Background Despite high expression of PD-L1, around half of advanced non-small cell lung
cancer (NSCLC) will not experience tumor response with pembrolizumab. There is an need …

Simple Summary There is an unmet need for new predictive biomarkers associated with
efficacy and immune-related toxicity of immune checkpoint inhibitors (ICIs) in non-small cell …